Filtreler
2019-12-23

Unal A. | Sutlas P.N. | Kuscu D.Y. | Emre U. | Yazar T. | Ankarali H. | Kirbas D.

Article | 2009 | Neurology Psychiatry and Brain Research16 ( 2 ) , pp.69 - 74

Background: Glucocorticoid treatment is recommended as the first-line treatment of MS relapses, however there is still no clear evidence supporting an optimum therapeutic regime. The high dose (HD) consisted of at least 500 mg/day, but the total dose of intravenous MP administered and the regimen varied among studies. The aim of this study was to assess the improvement following a standard regime of IVMP (1 g/day MP given for 10 days, without tapering) for MS relapses. A second objective was to search baseline predictors of outcome. Method: Consecutive treatments with IVMP for ten days (1 g/day, single dose in 150cc. saline, over 40 . . . min) administered at our Neurology clinic for an episode of acute neurological deterioration in 44 patients (55 relapses) diagnosed with RR MS were recruited retrospectively. Results: Attack severity was mild in three, moderate in 28 and severe in 24 relapses. Significant improvement (? 1.0 EDSS point) occurred in 81 % of attacks at one month. The rate of improvement at ten days was 83.6%, and 85.5% at six months. There was no difference in means of latency to treatment between the patients that responded well to therapy and responded poor, at the first month. However response to therapy was higher at the sixth month in patients with latency to treatment shorter than fifteen days (68.4%, 94.4%). Conclusions: In conclusion the results of our retrospectively designed clinical study support that HD MP, 1 g/day for ten days administered IV can accelerate the recovery from MS relapses. This regimen with proper early timing for starting therapy might determine the optimum benefit. © Universitätsverlag Ulm GmbH 2009 Daha fazlası Daha az

Evaluation of tularaemia courses: A multicentre study from Turkey

Erdem H. | Ozturk-Engin D. | Yesilyurt M. | Karabay O. | Elaldi N. | Celebi G. | Korkmaz N.

Article | 2014 | Clinical Microbiology and Infection20 ( 12 ) , pp.69 - 74

In this multicentre study, which is the largest case series ever reported, we aimed to describe the features of tularaemia to provide detailed information. We retrospectively included 1034 patients from 41 medical centres. Before the definite diagnosis of tularaemia, tonsillitis (n = 653, 63%) and/or pharyngitis (n = 146, 14%) were the most frequent preliminary diagnoses. The most frequent clinical presentations were oropharyngeal (n = 832, 85.3%), glandular (n = 136, 13.1%) and oculoglandular (n = 105, 10.1%) forms. In 987 patients (95.5%), the lymph nodes were reported to be enlarged, most frequently at the cervical chain jugular . . .(n = 599, 58%), submandibular (n = 401, 39%), and periauricular (n = 55, 5%). Ultrasound imaging showed hyperechoic and hypoechoic patterns (59% and 25%, respectively). Granulomatous inflammation was the most frequent histological finding (56%). The patients were previously given antibiotics for 1176 episodes, mostly with ß-lactam/ß-lactamase inhibitors (n = 793, 76%). Antituberculosis medications were provided in seven (2%) cases. The patients were given rational antibiotics for tularaemia after the start of symptoms, with a mean of 26.8 ± 37.5 days. Treatment failure was considered to have occurred in 495 patients (48%). The most frequent reasons for failure were the production of suppuration in the lymph nodes after the start of treatment (n = 426, 86.1%), the formation of new lymphadenomegalies under treatment (n = 146, 29.5%), and persisting complaints despite 2 weeks of treatment (n = 77, 15.6%). Fine-needle aspiration was performed in 521 patients (50%) as the most frequent drainage method. In conclusion, tularaemia is a long-lasting but curable disease in this part of the world. However, the treatment strategy still needs optimization. © 2014 European Society of Clinical Microbiology and Infectious Diseases Daha fazlası Daha az

Calculation of productions of medical 201Pb, 198Au, 186Re, 111Ag, 103Pd, 90Y, 89Sr, 77Kr, 77As, 67Cu, 64Cu, 47Sc and 32P nuclei used in cancer therapy via phenomenological and microscopic level density models

Artun O.

Article | 2019 | Applied Radiation and Isotopes144 , pp.64 - 79

In the present study, we have widely investigated the production of nuclei used in cancer therapy for both phenomenological and microscopic level density models via TALYS and EMPIRE codes. To estimate the production of the radioisotope, we calculated the cross-section curves of the reaction and the integral yield curves for nine level density models using the cross-sections and the mass-stopping powers acquired from X-PMSP program in the particle beam current of 1 µA and irradiation time 1 h. To discuss the obtained results on the basis of the cross-sections and the integral yields curves, the results were compared with the experime . . .ntal data and the recommended data in the literature. © 2018 Elsevier Lt Daha fazlası Daha az

Calculation of productions of medical Pb-201, Au-198, Re-186, Ag-111, (103)pd, Y-90, Sr-89, Kr-77, Cu-77, Cu-67, Cu-64, Sc-47 and P-32 nuclei used in cancer therapy via phenomenological and microscopic level density models

Artun, Ozan

Article | 2019 | APPLIED RADIATION AND ISOTOPES144 , pp.64 - 79

In the present study, we have widely investigated the production of nuclei used in cancer therapy for both phenomenological and microscopic level density models via TALYS and EMPIRE codes. To estimate the production of the radioisotope, we calculated the cross-section curves of the reaction and the integral yield curves for nine level density models using the cross-sections and the mass-stopping powers acquired from X-PMSP program in the particle beam current of 1 mu A and irradiation time 1 h. To discuss the obtained results on the basis of the cross-sections and the integral yields curves, the results were compared with the experi . . .mental data and the recommended data in the literature Daha fazlası Daha az

6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms